Neurotrophic Keratitis

• FDA approval · 2023-10-20
  FDA Approved: OXERVATE — Supplemental Application (Domp farmaceutici S.p.A.)

  FDA approves a supplemental application for Oxervate (cenegermin-bkbj) from Domp farmaceutici S.p.A., marking FDA approval of the requested …

• FDA approval · 2019-10-30
  FDA Approved: OXERVATE — Supplemental Application (Domp farmaceutici S.p.A.)

  FDA approved a supplemental application for Oxervate (cenegermin-bkbj) submitted by Dompé farmaceutici S.p.A.

• FDA approval · 2018-08-22
  FDA Approved: OXERVATE — Original Application (Domp farmaceutici S.p.A.)

  FDA approved Oxervate (cenegermin-bkbj) from Dompé Farmaceutici as a first-in-class therapy for neurotrophic keratitis, a rare corneal disea…